Eastgate Biotech Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Eastgate Biotech's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2017 |
Recent past performance updates
No updates
Recent updates
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Eastgate Biotech has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
Show sectionRevenue & Expenses BreakdownBeta
How Eastgate Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 17 | 0 | -4 | 3 | 0 |
| 30 Jun 17 | 0 | -3 | 2 | 1 |
| 31 Mar 17 | 0 | -2 | 2 | 1 |
| 31 Dec 16 | 0 | -3 | 2 | 1 |
| 30 Sep 16 | 0 | -3 | 2 | 1 |
| 30 Jun 16 | 0 | -4 | 3 | 1 |
| 31 Mar 16 | 0 | -4 | 3 | 1 |
| 31 Dec 15 | 0 | -4 | 3 | 1 |
| 30 Sep 15 | 0 | -5 | 3 | 1 |
| 30 Jun 15 | 0 | -5 | 3 | 1 |
| 31 Mar 15 | 0 | -6 | 4 | 1 |
| 31 Dec 14 | 0 | -5 | 4 | 1 |
| 30 Sep 14 | 0 | -5 | 4 | 1 |
| 30 Jun 14 | 0 | -4 | 4 | 0 |
| 31 Mar 14 | 0 | -3 | 2 | 0 |
| 31 Dec 13 | 0 | -2 | 2 | 0 |
| 30 Sep 13 | 0 | -1 | 1 | 0 |
Quality Earnings: Insufficient data to determine if ETBI has high quality earnings.
Growing Profit Margin: Insufficient data to determine if ETBI's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ETBI's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare ETBI's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if ETBI's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: ETBI has a negative Return on Equity (0%), as it is currently unprofitable.